看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: x# T9 M6 u9 E1 E1 ?2 h
) K( o3 I* T: e9 }
0 T! k' a$ }" Y# Q! JCurrently available feasibility data for possible combination strategies. * q* t# p1 G/ d* z
————————————————————————————————1 j( v; Y4 [. U/ ^; L
Combination Feasibility according to preliminary data 5 j% M& S4 p0 Y8 q5 ?7 p
——————————————————————————————————
$ v7 s6 I& C* zBevacizumab + sorafenib Yes, reduced dose & I, V, h' |; O! t6 C6 \/ ?1 R
Bevacizumab + sunitinib† No
+ t& e& K( p. W/ iBevacizumab + temsirolimus Yes
" C5 y$ H8 y' T# r1 DBevacizumab + everolimus Yes 7 A' t- r$ A; Q, @
Sorafenib + sunitinib ? , k- ]8 J8 J" k. f% j% e7 O2 l7 d# X3 n0 C
Sorafenib + temsirolimus Yes, reduced dose ) R. `" U' K8 ?' a5 k# N
Sorafenib + everolimus Yes, reduced dose 0 L1 f* U& k, M \: l2 E3 g" R6 q0 ?
Sunitinib + temsirolimus† No # ?/ v2 C. l# G: U7 n
Sunitinib + everolimus ?
$ J. N! t _( [/ |Temsirolimus + everolimus ?
) J) P! f: ^ n" B+ c$ R% V————————————————————) Y& H) n6 N( I, r) B7 Q5 O
†Led to US FDA warning.: k% R% G% K% y. k: c. O+ }& C
?: As yet unattempted combination.
# a- U7 ]1 b S$ k |